Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30743
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSerrano, Antonin-
dc.contributor.authorBerthelet, Jean-
dc.contributor.authorNaik, Shalin H-
dc.contributor.authorMerino, Delphine-
dc.date2022-
dc.date.accessioned2022-08-25T05:17:37Z-
dc.date.available2022-08-25T05:17:37Z-
dc.date.issued2022-08-18-
dc.identifier.citationNature Reviews. Cancer 2022; 22(11)en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/30743-
dc.description.abstractTumours are often composed of a multitude of malignant clones that are genomically unique, and only a few of them may have the ability to escape cancer therapy and grow as symptomatic lesions. As a result, tumours with a large degree of genomic diversity have a higher chance of leading to patient death. However, clonal fate can be driven by non-genomic features. In this context, new technologies are emerging not only to track the spatiotemporal fate of individual cells and their progeny but also to study their molecular features using various omics analysis. In particular, the recent development of cellular barcoding facilitates the labelling of tens to millions of cancer clones and enables the identification of the complex mechanisms associated with clonal fate in different microenvironments and in response to therapy. In this Review, we highlight the recent discoveries made using lentiviral-based cellular barcoding techniques, namely genetic and optical barcoding. We also emphasize the strengths and limitations of each of these technologies and discuss some of the key concepts that must be taken into consideration when one is designing barcoding experiments. Finally, we suggest new directions to further improve the use of these technologies in cancer research.en
dc.language.isoeng-
dc.titleMastering the use of cellular barcoding to explore cancer heterogeneity.en
dc.typeJournal Articleen
dc.identifier.journaltitleNature Reviews. Canceren
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen
dc.identifier.affiliationDepartment of Medical Biology, Faculty of Medicine, Dentistry and Health Science, The University of Melbourne, Parkville, Victoria, Australiaen
dc.identifier.affiliationImmunology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australiaen
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australiaen
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/35982229/en
dc.identifier.doi10.1038/s41568-022-00500-2en
dc.type.contentTexten
dc.identifier.orcidhttp://orcid.org/0000-0002-8178-6441en
dc.identifier.orcidhttp://orcid.org/0000-0003-2562-0575en
dc.identifier.orcidhttp://orcid.org/0000-0003-0299-3301en
dc.identifier.orcidhttp://orcid.org/0000-0002-8075-6275en
dc.identifier.pubmedid35982229-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.languageiso639-1en-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

60
checked on Jan 7, 2025

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.